-
公开(公告)号：US08236559B2
公开(公告)日：2012-08-07
申请号：US12210313
申请日：2008-09-15
Applicant: Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
Inventor： Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
IPC: C12N5/16
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Abstract translation: 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
公开(公告)号：US20090324605A1
公开(公告)日：2009-12-31
申请号：US12551250
申请日：2009-08-31
Applicant: Alison Witte , Denise Williams , Josephine M. Cardarelli , David King , David Passmore
Inventor： Alison Witte , Denise Williams , Josephine M. Cardarelli , David King , David Passmore
IPC: A61K39/395 , C07K16/24 , A61P3/10 , A61P19/02 , C07H21/04 , C12N15/63 , C12N5/10 , A01K67/027 , C12N5/12
CPC classification number: C07K16/249 , A61K51/1021 , A61K2039/505 , C07K16/24 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76
Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
Abstract translation: 本发明提供分离的抗干扰素α单克隆抗体，特别是人单克隆抗体，其抑制多种干扰素（IFN）α亚型的生物学活性，但基本上不抑制IFNα21的生物活性或IFNβ的生物学活性 或IFNγ。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制IFNα的生物学活性的方法，以及通过施用本发明的抗体来治疗由IFNα介导的疾病或病症的方法，例如自身免疫疾病，移植排斥反应和移植物抗宿主病 本发明的抗体。
-
公开(公告)号：US08518407B2
公开(公告)日：2013-08-27
申请号：US13450126
申请日：2012-04-18
Applicant: Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
Inventor： Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
IPC: A61K39/395
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Abstract translation: 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
公开(公告)号：US08481683B2
公开(公告)日：2013-07-09
申请号：US12517183
申请日：2007-11-30
Applicant: David John King , Alison Witte , Heidi N. LeBlanc , Richard Theolis , Asna Masood , Mark Yamanaka , Kyra D. Zens , Sarah R. Reed , Tim Sproul , Chetana Rao-Naik , David Passmore , Dawn M. Tanamachi , Kristopher Toy
Inventor： David John King , Alison Witte , Heidi N. LeBlanc , Richard Theolis , Asna Masood , Mark Yamanaka , Kyra D. Zens , Sarah R. Reed , Tim Sproul , Chetana Rao-Naik , David Passmore , Dawn M. Tanamachi , Kristopher Toy
IPC: C12P21/08 , C07K16/00 , A61K39/395 , A61K39/40 , C07K1/00
CPC classification number: C07K16/2803 , A61K39/39558 , A61K45/06 , A61K47/6829 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/3061 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
Abstract translation: 本公开提供了以高亲和力特别是人单克隆抗体特异性结合CD22的分离的单克隆抗体。 还提供编码本公开的抗体的核酸分子，表达载体，宿主细胞和用于表达本公开的抗体的方法。 还提供了抗体 - 配偶体分子缀合物，双特异性分子和包含本公开的抗体的药物组合物。 本公开还提供了用于检测CD22的方法，以及使用本公开的抗CD22抗体治疗各种癌症和炎性和自身免疫性疾病的方法。
-
公开(公告)号：US20120269824A1
公开(公告)日：2012-10-25
申请号：US13450126
申请日：2012-04-18
Applicant: Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
Inventor： Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
IPC: A61K39/395 , A61P19/02 , A61P29/00 , C07K16/28
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Abstract translation: 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
Patent Agency Ranking
公开(公告)号：US20110300145A1
公开(公告)日：2011-12-08
申请号：US13211092
申请日：2011-08-16
Applicant: ALISON WITTE , DENISE WILLIAMS , JOSEPHINE M. CARDARELLI , DAVID KING , DAVID PASSMORE
Inventor： ALISON WITTE , DENISE WILLIAMS , JOSEPHINE M. CARDARELLI , DAVID KING , DAVID PASSMORE
IPC: A61K39/395 , A61P25/00 , A61P1/00 , A61P37/06 , A61P17/06 , A61P5/14 , A61P29/00 , A61P13/12 , A61P19/04 , A61P3/10
CPC classification number: C07K16/249 , A61K51/1021 , A61K2039/505 , C07K16/24 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76
Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
Abstract translation: 本发明提供分离的抗干扰素α单克隆抗体，特别是人单克隆抗体，其抑制多种干扰素（IFN）α亚型的生物学活性，但基本上不抑制IFNα21的生物活性或IFNβ的生物学活性 或IFNγ。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制IFNα的生物学活性的方法，以及通过施用本发明的抗体来治疗由IFNα介导的疾病或病症的方法，例如自身免疫疾病，移植排斥反应和移植物抗宿主病 本发明的抗体。
-
公开(公告)号：US20100143369A1
公开(公告)日：2010-06-10
申请号：US12704948
申请日：2010-02-12
Applicant: Josephine M. Cardarelli , Alison Witte , Mohan Srinivasan
Inventor： Josephine M. Cardarelli , Alison Witte , Mohan Srinivasan
IPC: A61K39/395 , A61P37/06
CPC classification number: C07K16/2866 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
Abstract translation: 本发明提供了与IFNAR-1结合并且能够抑制I型干扰素的生物活性的分离的人单克隆抗体。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制I型干扰素介导的病症的方法，包括使用本发明的抗体治疗自身免疫疾病，移植排斥或移植物抗宿主病的方法。
-
公开(公告)号：US20100143368A1
公开(公告)日：2010-06-10
申请号：US12517183
申请日：2007-11-30
Applicant: David John King , Alison Witte , Heidi N. LeBlanc , Richard Theolis , Asna Masood , Mark Yamanaka , Kyra D. Emory , Sarah R. Reed , Tim Sproul , Chetana Rao-Naik , David Passmore
Inventor： David John King , Alison Witte , Heidi N. LeBlanc , Richard Theolis , Asna Masood , Mark Yamanaka , Kyra D. Emory , Sarah R. Reed , Tim Sproul , Chetana Rao-Naik , David Passmore
CPC classification number: C07K16/2803 , A61K39/39558 , A61K45/06 , A61K47/6829 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/3061 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
Abstract translation: 本公开提供了以高亲和力特别是人单克隆抗体特异性结合CD22的分离的单克隆抗体。 还提供了编码本公开的抗体的核酸分子，表达载体，宿主细胞和用于表达本公开的抗体的方法。 还提供了抗体 - 配偶体分子缀合物，双特异性分子和包含本公开的抗体的药物组合物。 本公开还提供了用于检测CD22的方法，以及使用本公开的抗CD22抗体治疗各种癌症和炎性和自身免疫性疾病的方法。
-
公开(公告)号：US20090214559A1
公开(公告)日：2009-08-27
申请号：US12210313
申请日：2008-09-15
Applicant: Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
Inventor： Brian Varnum , Chris Vezina , Alison Witte , Xueming Qian , Francis Hall Martin , Haichun Huang , Gary Elliott
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Abstract translation: 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
公开(公告)号：US20060029601A1
公开(公告)日：2006-02-09
申请号：US11157494
申请日：2005-06-20
Applicant: Josephine Cardarelli , Alison Witte , Mohan Srinivasan
Inventor： Josephine Cardarelli , Alison Witte , Mohan Srinivasan
IPC: A61K39/395 , C07K16/28
CPC classification number: C07K16/2866 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
Abstract translation: 本发明提供了与IFNAR-1结合并且能够抑制I型干扰素的生物活性的分离的人单克隆抗体。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制I型干扰素介导的病症的方法，包括使用本发明的抗体治疗自身免疫疾病，移植排斥或移植物抗宿主病的方法。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.045 seconds)
